Adial pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Adial pharmaceuticals Contact Number

Adial Pharmaceuticals Inc. Contact Us

6 hours ago Adialpharma.com Show details

(434) 422-9800Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Ste 495 Charlottesville, VA 22901. Email: [email protected] Phone: (434) 422-9800

1. 1180 Seminole Trl Ste 495, Charlottesville, VA 22901

Category: Contact SupportShow more

Adial Pharmaceuticals Crunchbase Company Profile & …

1 hours ago Crunchbase.com Show details

434-422-9800Contact Email [email protected] Phone Number 434-422-9800. Adial Pharmaceuticals, LLC engages in the development of prescription medications for addiction and related disorders in the United States. The company's research pipeline includes AD04, a compound that completed Phase IIb study for the treatment of alcohol use disorders; and AD01

Founders: Bankole Johnson, William B Stilley

Category: Contact NumberShow more

Adial Pharmaceuticals (nasdaq: Adil) Email & Phone of

8 hours ago Easyleadz.com Show details

Adial Pharmaceuticals (nasdaq: Adil) - email id & phone of top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head & all company details.

Headquarters : Charlottesville, Virginia, United States
Name : Adial Pharmaceuticals (nasdaq: Adil)
Industry : Pharmaceuticals
Location: Charlottesville, Virginia

Category: Phone NumberShow more

Adial Pharmaceuticals Inc. Medicines for Addiction

8 hours ago Adialpharma.com Show details

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).

Category: Contact NumberShow more

Adial Pharmaceuticals Overview, News & Competitors

2 hours ago Zoominfo.com Show details

(434) 422-9800Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …

Employees: 25
Phone: (434) 422-9800
Location: 1180 Seminole Trl, Ste 495, Charlottesville, 22901, Virginia

Category: Contact NumberShow more

ADIAL PHARMACEUTICALS, INC. (Form: 8K, Received: 02/01

7 hours ago Content.edgar-online.com Show details

900-21-0058Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) the number of membership interests in the Company to be sold to Purchaser by the Member Contact: Crescendo Communications, LLC. David Waldman / Natalya Rudman. Tel: 212-671-1021.

Category: Contact NumberShow more

Adial Pharmaceuticals Inc ZIP 22901, NAICS 446110

4 hours ago Siccode.com Show details

"Adial Pharmaceuticals Inc" of Charlottesville, VA 22901 operates primarily in SIC Code 5912 - Drug Stores and Proprietary Stores and NAICS Code 446110 - Pharmacies and Drug Stores. Adial Pharmaceuticals Inc is a small-sized business with medium revenue, that is established in …

Category: Contact NumberShow more

EIN 800667150 Adial Pharmaceuticals, Inc

9 hours ago Eintaxid.com Show details

Adial Pharmaceuticals, Inc. is a corporation in Charlottesville, Virginia. The employer identification number (EIN) for Adial Pharmaceuticals, Inc. is 800667150. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC.

Category: Contact NumberShow more

Adial Pharmaceutical, Inc. (ADIL)

7 hours ago Ir.adialpharma.com Show details

Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder ("AUD") using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist (i.e., a "5-HT3 antagonist").

Category: Contact NumberShow more

Adial Pharmaceuticals Provides Update on ONWARD™ Phase 3

7 hours ago Ir.adialpharma.com Show details

Landmark Trial Addressing Global Interest in Reducing Alcohol Addiction. CHARLOTTESVILLE, VA / ACCESSWIRE / April 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its landmark …

Category: Contact NumberShow more

Adial Pharmaceuticals, Inc. (ADIL) Company Profile & Facts

5 hours ago Finance.yahoo.com Show details

See the company profile for Adial Pharmaceuticals, Inc. (ADIL) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives

Category: Contact NumberShow more

Adial Pharmaceuticals Home Facebook

7 hours ago Facebook.com Show details

Adial Pharmaceuticals. Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share Download as PDF July 07, 2021 CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments fo

Category: Home PhoneShow more

ADIAL PHARMACEUTICALS, INC. (Form: 8K, Received: 11/03

4 hours ago Content.edgar-online.com Show details

900-20-0346Item 7.01. Regulation FD Disclosure. On November 3, 2020, Adial Pharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) providing an update regarding its landmark ONWARD™ Phase 3 pivotal trial (the “Trial”) investigating the Company’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in …

Category: Contact NumberShow more

SEC FORM D

4 hours ago Sec.gov Show details

(434) 422-9800ADIAL PHARMACEUTICALS, INC. Street Address 1 Street Address 2; 1180 SEMINOLE TRAIL, SUITE 495: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CHARLOTTESVILLE: VIRGINIA: 22901 (434) 422-9800

Category: Contact NumberShow more

ADILW Adial Pharmaceuticals Inc Warrant Stock Market MBA

6 hours ago Stockmarketmba.com Show details

ADILW Adial Pharmaceuticals Inc Warrant Expiring 2/2024 The warrants are exercisable upon issuance at a price of $4.0625 per share of common stock, subject to adjustment in certain circumstances, and will expire on February 26, 2024. This security was issued by Adial Pharmaceuticals Inc, whose common stock symbol is ADIL.

Category: Contact NumberShow more

Adial Pharmaceuticals : Announces Positive PreClinical

Just Now Marketscreener.com Show details

About Adial Pharmaceuticals, Inc. 2022, the Purnovate adenosine platform having the ability to underpin a drug development program addressing pain and a number of other prevalent ailments such as diabetes, asthma, cancer, Parkinson's Disease, inflammatory bowel disease, and infectious diseases where a cytokine storm is a significant

Category: Contact NumberShow more

Adial Pharmaceuticals (ADIL) Stock Message Board

4 hours ago Investorshub.advfn.com Show details

212-671-1021Contact: For Adial Pharmaceuticals, Inc.Crescendo Communications, LLCDavid Waldman / Natalya RudmanTel: 212-671-1021Email: [email protected] For iRemedy Healthcare Companies, Inc.Keisha GrahamTel: [email protected] SOURCE: Adial Pharmaceuticals, Inc.

Category: Contact NumberShow more

Adial Announces Cary J. Claiborne, a Renowned

8 hours ago Finance.yahoo.com Show details

CHARLOTTESVILLE, Va., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the

Category: Contact NumberShow more

Adial Pharmaceuticals Plans to Enter Genetic Testing

3 hours ago Bloomberg.com Show details

021-06-22Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test The Company believes the genetic companion diagnostic test for AD04 for

Category: Contact NumberShow more

Jobs with ADial Pharmaceuticals BioSpace

3 hours ago Biospace.com Show details

58 articles with ADial Pharmaceuticals. Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share. 12/22/2021. Adial Pharmaceuticals, Inc. today announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021 (the “Offering”).

Category: Contact NumberShow more

Adial Pharmaceuticals Completes Private Placement of

8 hours ago Ca.finance.yahoo.com Show details

CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received the balance of $720,000 …

Category: Contact NumberShow more

FORM D SEC

4 hours ago Sec.gov Show details

Name of Issuer; ADial Pharmaceuticals, L.L.C. Street Address 1 Street Address 2; 204 E. HIGH STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer

Category: Contact NumberShow more

The clock is ticking: Adial Pharmaceuticals Inc. (ADIL

1 hours ago Investchronicle.com Show details

For the readers interested in the stock health of Adial Pharmaceuticals Inc. (ADIL). It is currently valued at $2.56. When the transactions were called off in the previous session, Stock hit the highs of $2.8899, after setting-off with the price of $2.84. Company’s stock value dipped to $2.47 duri

Category: Contact NumberShow more

Adial Pharmaceuticals Number of Employees 20172021 ADIL

8 hours ago Macrotrends.net Show details

Adial Pharmaceuticals number of employees from 2017 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company.

Category: Contact NumberShow more

Analysts Expect Adial Pharmaceuticals, Inc. (NASDAQ:ADIL

1 hours ago Marketbeat.com Show details

The stock has a 50 day moving average of $3.14 and a 200 day moving average of $3.21. Adial Pharmaceuticals has a 12 month low of $1.60 and a 12 month high of $5.08. Adial Pharmaceuticals Company Profile. Adial Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder.

Category: Contact NumberShow more

Adial Pharmaceuticals (ADIL) Completes Private Placement

6 hours ago Streetinsider.com Show details

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of

Category: Contact NumberShow more

Adial Pharmaceuticals Awarded U.S. and International

Just Now Globenewswire.com Show details

Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04. August 10, 2021 09:30 ET Source: Adial Pharmaceuticals, Inc. Adial

Category: Contact NumberShow more

Adial Pharmaceuticals (NASDAQ:ADIL) Upgraded to Buy at

Just Now Marketbeat.com Show details

A number of other research firms also recently commented on ADIL. Litchfield Hills Research reaffirmed a "buy" rating on shares of Adial Pharmaceuticals in a research report on Tuesday, November 30th. Brookline Capital Acquisition began coverage on shares of Adial Pharmaceuticals in a research report on Wednesday, October 13th.

Category: Contact NumberShow more

Adial Appoints Renowned Pharmaceutical Executive Cary J.

3 hours ago Globenewswire.com Show details

Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors. CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW

Category: Contact NumberShow more

ADIL Stock Price ADial Pharmaceuticals Inc. Stock Quote

8 hours ago Marketwatch.com Show details

Adial Pharmaceuticals Inc (ADIL) CEO William B. Stilley Iii Bought $55,002 of Shares Dec. 1, 2021 at 12:15 p.m. ET on GuruFocus.com Adial Pharmaceuticals (ADIL) …

Category: Contact NumberShow more

Statement of Changes in Beneficial Ownership (4)

4 hours ago Ih.advfn.com Show details

The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 (2)

Category: Contact NumberShow more

Adial Announces Cary J. Claiborne, a Renowned

1 hours ago Au.finance.yahoo.com Show details

CHARLOTTESVILLE, Va., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne as Chief Operating Officer. …

Category: Contact NumberShow more

Statement of Changes in Beneficial Ownership (4)

4 hours ago Ih.advfn.com Show details

Statement of Changes in Beneficial Ownership (4) November 30 2021 - 09:26AM. Edgar (US Regulatory) FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1 (b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 STATEMENT OF CHANGES IN …

Category: Contact NumberShow more

Adial Pharmaceuticals (ADIL) Denied FDA Fast Track

6 hours ago Investorsobserver.com Show details

Based on this feedback, Adial will review the additional requirements and data requested by the FDA for a Fast Track Designation. AD04 is undergoing a Phase 3 ONWARD trial. The primary endpoint of efficacy is the change from baseline in the monthly number of heavy drinking days during the last eight weeks of the 24-week treatment period.

Category: Contact NumberShow more

Vanguard Group Inc reports 1.61% increase in ownership of

3 hours ago Fintel.io Show details

(Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00688A 106 (CUSIP Number) William B. Stilley, III c/o Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Suite 495 Charlottesville, Virginia 22901 (43

Category: Contact NumberShow more

ADIL Adial Pharmaceuticals Stock Price Barchart.com

2 hours ago Barchart.com Show details

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

Category: Contact NumberShow more

Adial Pharmaceuticals Announces Greater Than 50% of

9 hours ago Apnews.com Show details

CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces that greater than 50% of patients expected to …

Category: Contact NumberShow more

ADIL ADial Pharmaceuticals Inc. Stock Price & News WSJ

3 hours ago Wsj.com Show details

News ADial Pharmaceuticals Inc.ADIL. No news for in the past two years. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price

Category: Contact NumberShow more

Adial Pharmaceuticals : Completes Private Placement of

4 hours ago Marketscreener.com Show details

Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share. Charlottesville, VA - December 22, 2021 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, …

Category: Contact NumberShow more

Adial Pharmaceuticals Enters Agreement to Acquire

9 hours ago Bloomberg.com Show details

020-12-10Contact: Crescendo Communications, LLC David Waldman / Natalya Rudman Tel: 212-671-1021 Email: [email protected] SOURCE: Adial Pharmaceutical, Inc. View source version on accesswire.com: https

Category: Contact NumberShow more

Should Biotechnology Stock Adial Pharmaceuticals Inc (ADIL

8 hours ago Investorsobserver.com Show details

Adial Pharmaceuticals Inc (ADIL) stock is trading at $3.83 as of 10:55 AM on Tuesday, Oct 5, a rise of $0.07, or 1.98% from the previous closing price of $3.76. The stock has traded between $3.73 and $3.86 so far today. Volume today is below average.

Category: Tech SupportShow more

Adial Pharmaceuticals Inc. (via Public) / Supplemental

1 hours ago Publicnow.com Show details

ADial Pharmaceuticals, L.L.C. converted from a Virginia limited liability company into a Virginia corporation on October 3, 2017, and then reincorporated in Delaware on October 11, 2017 by merging the Virginia Corporation with and into Adial Pharmaceuticals, Inc., a Delaware corporation that was incorporated on October 5, 2017 as a wholly owned

Category: Contact NumberShow more

Breaking News: ADIL latest news. The Fly

9 hours ago Thefly.com Show details

Adial Pharmaceuticals…. Adial Pharmaceuticals announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021. The shares of common stock sold in the Offering were priced at $4.00 per share and a total of 200,000 shares were purchased in the Offering.

Category: Contact NumberShow more

Adial Announces Positive PreClinical Data for Purnovate's

5 hours ago Marketwatch.com Show details

021-10-21Press Release Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as a Drug Candidate for the Treatment of Pain Published: Oct. 21, 2021 at 10:14 a.m. ET

Category: Contact NumberShow more

Adial Pharmaceuticals (NasdaqCM:ADIL) Share price, News

9 hours ago Simplywall.st Show details

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc. On December 22, 2021, Adial Pharmaceuticals, Inc closed the transaction. The company issued 180,000 shares for gross proceeds of $720,000 in its final tranche. Dec 02.

Category: Contact NumberShow more

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD

Just Now Stocktitan.net Show details

Do NOT follow this link! August 31, 2021 - 9:30 am. ONWARD trial enrollment closed; trial completion expected in Q1 2022. CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for …

Category: Contact NumberShow more

Adial Joins Russell Microcap® Index

6 hours ago Apnews.com Show details

Adial’s addition to the Russell Microcap Index follows the annual Russell indexes reconstitution according to a final list of additions posted on June 25, 2021. Adial’s membership in the Russell Microcap® Index is effective at Nasdaq market open, today, June 28, 2021.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What does Adial pharmaceuticals do?

Something went wrong while loading Watchlist. Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist.

What is Adial’s strategy for AD04?

Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.

Can AD04 be used to treat Auditory Processing Disorder (AUD)?

Adial has commenced a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

What is adadial's goal?

Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment. This opens in a new window.

Popular Brands

Amazon
Abbvie
Asml
Aia
Att
Apple
Amgen
Adobe
Aptar
Acc
Adidas
Aak